Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab.
Faguer
S
S
Launay
F
F
Ysebaert
L
L
Mailhol
C
C
Estines-Chartier
O
O
Lamant
L
L
Paul
C
C
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018450:Disease Progression; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab